These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2199431)

  • 1. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
    Mazure CM; Nelson JC; Jatlow PI; Kincare P; Bowers MB
    J Clin Psychiatry; 1990 Aug; 51(8):330-4. PubMed ID: 2199431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():29-40. PubMed ID: 3907279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Auken G; Waehrens J; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():15-28. PubMed ID: 3907278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of extrapyramidal symptoms during acute neuroleptic treatment.
    Mazure CM; Cellar JS; Bowers MB; Nelson JC; Takeshita J; Zigun B
    J Clin Psychiatry; 1995 Mar; 56(3):94-100. PubMed ID: 7883736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clozapine, negative symptoms, and extrapyramidal side effects.
    Kane JM; Safferman AZ; Pollack S; Johns C; Szymanski S; Kronig M; Lieberman JA
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():74-7. PubMed ID: 7961579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of serum molindone levels to serum prolactin levels and antipsychotic response.
    Pandurangi AK; Narasimhachari N; Blackard WG; Landa BS
    J Clin Psychiatry; 1989 Oct; 50(10):379-81. PubMed ID: 2676994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-responsive symptoms during early neuroleptic treatment.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Psychiatry Res; 1992 Feb; 41(2):147-54. PubMed ID: 1574541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting-test study in 22 acutely ill schizophrenic patients.
    Gerken A; Wetzel H; Benkert O
    Pharmacopsychiatry; 1991 Jul; 24(4):132-7. PubMed ID: 1754609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
    Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
    Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
    Neborsky RJ; Janowsky DS; Perel JM; Munson E; Depry D
    J Clin Psychiatry; 1984 Jan; 45(1):10-3. PubMed ID: 6363395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
    J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trifluoperazine plasma levels and clinical response.
    Janicak PG; Javaid JI; Sharma RP; Comaty JE; Peterson J; Davis JM
    J Clin Psychopharmacol; 1989 Oct; 9(5):340-6. PubMed ID: 2794098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial response to antipsychotic treatment: the patient with enduring symptoms.
    Emsley RA
    J Clin Psychiatry; 1999; 60 Suppl 23():10-3. PubMed ID: 10625194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():41-50. PubMed ID: 3934921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
    Kasper S
    J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of neuroleptic blood levels in the treatment of acute psychosis.
    Zohar J; Shemesh Z; Belmaker RH
    J Clin Psychiatry; 1986 Dec; 47(12):600-3. PubMed ID: 3782046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acutely psychotic patients receiving high-dose haloperidol therapy.
    Remington G; Pollock B; Voineskos G; Reed K; Coulter K
    J Clin Psychopharmacol; 1993 Feb; 13(1):41-5. PubMed ID: 8486816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial.
    Goff DC; Arana GW; Greenblatt DJ; Dupont R; Ornsteen M; Harmatz JS; Shader RI
    J Clin Psychopharmacol; 1991 Apr; 11(2):106-12. PubMed ID: 2056136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.
    Hansen LB; Larsen NE; Vestergård P
    Psychopharmacology (Berl); 1981; 74(4):306-9. PubMed ID: 6794071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.